Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Exp Mol Med ; 51(7): 1-18, 2019 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-31263178

RESUMO

Renal osteodystrophy (ROD) occurs as early as chronic kidney disease (CKD) stage 2 and seems ubiquitous in almost all pediatric patients with CKD stage 5. Fibroblast growth factor (FGF)-23, a bone-derived endocrine regulator of phosphate homeostasis, is overexpressed in CKD and disturbs osteoblast differentiation and matrix mineralization. In contrast, C-type natriuretic peptide (CNP) acts as a potent positive regulator of bone growth. In the present study, we infused CNP into uremic rats and observed whether CNP could attenuate ROD through the inhibition of FGF-23 cascades. In uremic rats, CNP administration significantly alleviated renal dysfunction, calcium phosphate metabolic disorders, hypovitaminosis D, secondary hyperparathyroidism, the decrease in bone turnover markers and retarded bone pathological progression. More importantly, within FGF-23/mitogen-activated protein kinase (MAPK) signaling, the fibroblast growth factor receptor-1, Klotho and alternative (STAT-1/phospho-STAT-1) elements were upregulated by CNP, whereas FGF-23, RAF-1/phospho-RAF-1, and downstream (ERK/phospho-ERK and P38/phospho-P38) elements were paradoxically underexpressed in bone tissue. Therefore, CNP exerts a therapeutic effect on ROD through inhibition of FGF-23/MAPK signaling at the RAF-1 level.


Assuntos
Remodelação Óssea , Distúrbio Mineral e Ósseo na Doença Renal Crônica/tratamento farmacológico , Fatores de Crescimento de Fibroblastos/metabolismo , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Peptídeo Natriurético Tipo C/administração & dosagem , Animais , Osso e Ossos/patologia , Cálcio/sangue , Diferenciação Celular/efeitos dos fármacos , Distúrbio Mineral e Ósseo na Doença Renal Crônica/patologia , Modelos Animais de Doenças , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/genética , Regulação da Expressão Gênica , Humanos , Rim/patologia , Masculino , Proteínas Proto-Oncogênicas c-raf/genética , Proteínas Proto-Oncogênicas c-raf/metabolismo , Ratos , Ratos Sprague-Dawley , Regulação para Cima , Uremia
2.
Int J Mol Med ; 43(1): 535-546, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30365152

RESUMO

The purpose of the present study was to determine whether fibroblast growth factor (FGF)­23 could serve as a novel biomarker for renal osteodystrophy (ROD) progression. A rat model of ROD was induced by left nephrectomy plus intravenous injection of Adriamycin. Serum FGF­23 was determined using an enzyme­linked immunosorbent assay. Serum level and bone expression of FGF­23 were both significantly elevated in the ROD group at 24 h post­surgery. Serum FGF­23 was negatively correlated with calcium, phosphate, 25­hydroxyvitamin D, conventional bone biomarkers and bone collagen X. More importantly, serum FGF­23 was significantly associated with abnormalities in bone formation rate, osteoblasts, osteoclasts, trabecular volume thickness and osteoid volume. Therefore, FGF­23 may serve as a novel biomarker for ROD.


Assuntos
Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo , Distúrbio Mineral e Ósseo na Doença Renal Crônica/patologia , Progressão da Doença , Fatores de Crescimento de Fibroblastos/metabolismo , Animais , Biomarcadores/metabolismo , Osso e Ossos/metabolismo , Distúrbio Mineral e Ósseo na Doença Renal Crônica/sangue , Distúrbio Mineral e Ósseo na Doença Renal Crônica/fisiopatologia , Colágeno Tipo X/metabolismo , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/sangue , Glucuronidase/metabolismo , Rim/patologia , Rim/fisiopatologia , Testes de Função Renal , Proteínas Klotho , Masculino , Ratos Sprague-Dawley , Receptores de Fatores de Crescimento de Fibroblastos/metabolismo
3.
J Investig Med ; 66(5): 1-9, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29367254

RESUMO

C-type natriuretic peptide (CNP) is regarded as a local, paracrine hormone to regulate vascular tone and cell proliferation. Although several in vivo studies have documented that CNP exerts the inhibitory effects on mesangial cells (MCs) proliferation and collagen production, a limited number of studies exist about the resistance of CNP to MCs proliferation in vitro. Besides, whether its receptor signaling and neutral endopeptidase (NEP) are involved remains unclear. In the present study, human MCs were incubated in serum-containing medium in the absence or presence of CNP (0, 10 and 100 pM) for 24, 48 and 72 hours, respectively. CNP administration significantly suppresses MCs proliferation and collagen-IV (Col-IV) expression in a time-dependent and dose-dependent manner. As a down-stream signal molecule of CNP activation, the expressions of natriuretic peptide receptor (NPR)-B, cyclic guanosine monophosphate-dependent protein kinases II and NPR-C were obviously augmented, whereas NEP expression was significantly decreased after CNP treatment. In conclusion, receptor signaling and NEP are involved in the resistance of CNP to human mesangial proliferation and Col-IV expression.


Assuntos
Colágeno Tipo IV/metabolismo , Células Mesangiais/citologia , Células Mesangiais/metabolismo , Peptídeo Natriurético Tipo C/metabolismo , Neprilisina/metabolismo , Receptores do Fator Natriurético Atrial/metabolismo , Transdução de Sinais , Proliferação de Células , Células Cultivadas , Regulação para Baixo , Humanos
4.
Clin Chim Acta ; 471: 76-80, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28526535

RESUMO

BACKGROUND: Tumor necrosis factor (TNF) -α is of inflammatory cytokines produced chiefly by activated monocyte/macrophages, and has been implicated in the pathogenesis of Kawasaki disease (KD). We elucidated the relationship of plasma TNF-α with conventional inflammatory mediators, clinical classification, intravenous immunoglobulin (IVIG) response and coronary arteritis in the course of KD. METHODS: Seventy Chinese children with KD were enrolled and divided into 6 subgroups, including complete KD, incomplete KD, IVIG-responsive KD, IVIG-nonresponsive KD, coronary artery (CA) -noninvolvement KD and CA-involvement KD. Blood samples were collected from all subjects at 24h pre- and 48h post-IVIG therapy, respectively. TNF-α, white blood cells counts (WBC), absolute neutrophil counts (ANC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and procalcitonin (PCT) were detected. RESULTS: Plasma TNF-α markedly increased in the acute phase of KD and was positively correlated with CRP and PCT, whereas remained high after IVIG therapy. TNF-α as well as conventional inflammatory mediators could not be used to differentiate the clinical classification of KD, but they may prove beneficial to heighten or reduce the suspicion of incomplete KD. Plasma TNF-α was significantly higher in both IVIG-nonresponsive patients and coronary arteritis patients, but no significant differences were observed in all the other inflammatory mediators. Moreover, plasma TNF-α was positively correlated with the internal diameter of CA. CONCLUSIONS: TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with KD.


Assuntos
Arterite/complicações , Doença da Artéria Coronariana/complicações , Imunoglobulinas Intravenosas/uso terapêutico , Mediadores da Inflamação/sangue , Síndrome de Linfonodos Mucocutâneos/sangue , Síndrome de Linfonodos Mucocutâneos/tratamento farmacológico , Fator de Necrose Tumoral alfa/sangue , Arterite/diagnóstico , Pré-Escolar , Doença da Artéria Coronariana/diagnóstico , Feminino , Humanos , Masculino , Síndrome de Linfonodos Mucocutâneos/complicações , Prognóstico , Resultado do Tratamento
5.
Biomark Med ; 10(9): 999-1008, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27586401

RESUMO

Acute kidney injury (AKI) refers to a sudden decline in renal function. A growing body of evidence demonstrates that AKI is a risk factor for the future development or accelerated progression of chronic kidney disease (CKD), whereas the actual distinction between AKI and CKD remains unknown. CNP is predominantly present in the kidney and possesses multiple renoprotective properties. Urinary CNP excretion tends to be high in AKI, whereas back to the baseline in CKD. The dynamic changes in urinary CNP excretion may help detect underlying renal injury and remodeling both acutely and chronically.


Assuntos
Injúria Renal Aguda/diagnóstico , Biomarcadores/urina , Peptídeo Natriurético Tipo C/urina , Injúria Renal Aguda/fisiopatologia , Biomarcadores/sangue , Doença Crônica , Creatinina/sangue , Cistatina C/urina , Taxa de Filtração Glomerular , Receptor Celular 1 do Vírus da Hepatite A/análise , Humanos , Interleucina-18/urina , Lipocalina-2/urina , Modelos de Riscos Proporcionais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA